CRP as a marker of inflammation: Mitigation of Ulcerative Colitis in rats by Mesalazine and Coenzyme Q10.
Main Article Content
Abstract
Background: Ulcerative colitis is a global health issue with no definitive treatment options available. Mesalazine is one of the first-line therapies available, and Coenzyme Q10 is a cellular component with anti-inflammatory, antioxidant, and cell-healing properties. This study evaluated the anti-inflammatory potential of mesalazine and Coenzyme Q10, alone and in combination, and C-reactive protein was assessed as a parameter of acute inflammation. Methods: 48 rats were divided into 6 groups. Ulcerative colitis was experimentally induced in rats and mesalazine and Coenzyme Q10 were given alone and in combination according to the grouping of animals. The kit method measured C-reactive protein levels in serum after 7 days. Results: the group treated with a combination of mesalazine and coenzyme Q10 showed a maximum reduction in C-reactive protein levels with only 12.5% with positive or >6mg/dl levels as compared to 100% with positive or >6mg/dl value in the disease-control group. Conclusion: The study showed that the combination of mesalazine and coenzyme Q10 has synergistic potential in reducing inflammation in ulcerative colitis.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
1. Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA. 2023;330(10):951-965. doi: 10.1001/jama.2023.15389.
2. Kaluzna A, Olczyk P, Komosinska-Vassev K. The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis. J Clin Med. 2022;11(2):400. doi: 10.3390/jcm11020400.
3. Dharmasiri S, Garrido-Martin EM, Harris RJ, Bateman AC, Collins JE, Cummings JRF, et al. Human intestinal macrophages are involved in the pathology of both ulcerative colitis and Crohn disease. Inflamm Bowel Dis. 2021;27(10):1641-1652. doi: 10.1093/ibd/izab029.
4. Luo X, Villablanca EJ. Type 2 immunity in intestinal homeostasis and inflammatory bowel disease. Biochem Soc Trans. 2021;49(5):2371-2380. doi: 10.1042/BST20210535.
5. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56-66. doi: 10.1038/s41575-020-00360-x.
6. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-1544. doi: 10.1016/S0140-6736(16)31012-1.
7. Li L, Cheng R, Wu Y, Lin H, Gan H, Zhang H. Diagnosis and management of inflammatory bowel disease. J Evid Based Med. 2024;17(2):409-433. doi: 10.1111/jebm.12626.
8. Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2-17. doi: 10.1093/ecco-jcc/jjab178.
9. Li R, Huang X, Yang L, Liang X, Huang W, Lai KP, et al. Integrated analysis reveals the targets and mechanisms in immunosuppressive effect of mesalazine on ulcerative colitis. Front Nutr. 2022;9:867692. doi: 10.3389/fnut.2022.867692.
10. Beiranvand M. A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug. Inflammopharmacology. 2021;29(5):1279-1290. doi: 10.1007/s10787-021-00856-1.
11. McRae MP. Coenzyme Q10 supplementation in reducing inflammation: an umbrella review. J Chiropr Med. 2023;22(2):131-137. doi: 10.1016/j.jcm.2022.07.001.
12. Pirzada H, Hameed S, Afzal A, Ali KS, Malik M, Javaid MF. Effects of mesalazine and coenzyme Q10 on colonic histology in rat model of ulcerative colitis. Esculapio. 2024;20(3):360-365. doi: 10.51273/esc24.251320410.
13. Yang C, Merlin D. Unveiling colitis: a journey through the dextran sodium sulfate-induced model. Inflamm Bowel Dis. 2024;30(5):844-853. doi: 10.1093/ibd/izad312.
14. Sakurai T, Saruta M. Positioning and usefulness of biomarkers in inflammatory bowel disease. Digestion. 2023;104(1):30-41. doi: 10.1159/000527846.
15. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(5):661-665. doi: 10.1097/00054725-200409000-00026.
16. Hayashi Y, Aoyagi K, Morita I, Yamamoto C, Sakisaka S. Oral administration of mesalazine protects against mucosal injury and permeation in dextran sulfate sodium-induced colitis in rats. Scand J Gastroenterol. 2009;44(11):1323-1331. doi: 10.3109/00365520903262414.
17. Khodir AE, Atef H, Said E, ElKashef HA, Salem HA. Implication of Nrf2/HO-1 pathway in the coloprotective effect of coenzyme Q10 against experimentally induced ulcerative colitis. Inflammopharmacology. 2017;25(1):119-135. doi: 10.1007/s10787-016-0305-0.
18. Modesto R, Estarreja J, Silva I, Rocha J, Pinto R, Mateus V. Chemically induced colitis-associated cancer models in rodents for pharmacological modulation: a systematic review. J Clin Med. 2022;11(10):2739. doi: 10.3390/jcm11102739.
19. Pirzada H, Iqbal N, Fatima H, Rafique R, Malik M, Taimuri SZ. Mesalazine and coenzyme Q10: effects on disease activity index in ulcerative colitis. Esculapio. 2024;20(4):499-503. doi: 10.51273/esc24.251320314.
20. Hu LH, Fan YJ, Li Q, Guan JM, Qu B, Pei FH, et al. Bortezomib protects against dextran sulfate sodium-induced ulcerative colitis in mice. Mol Med Rep. 2017;15(6):4093-4099. doi: 10.3892/mmr.2017.6524.
21. Kamarli Altun H, Akal Yildiz E, Akin M. Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: a randomized placebo-controlled study. Turk J Gastroenterol. 2019;30(4):313-320. doi: 10.5152/tjg.2019.18356.